Merck signs patent licensing agreement with Sun Pharma for Januvia: Report

29 Jun 2013 Evaluate

US drug firm Merck Sharp & Dhome and Indian drug-maker Sun Pharmaceuticals Industries, who have a co-marketing tie up for former’s diabetes drug Januvia, reportedly have now signed a patent licensing agreement. The move will further strengthen the patent infringement suit that the two companies have filed against Glenmark after the latter launched generic versions of Merck’s diabetes drugs Januvia & Janumet in India.

US drug firm Merck has now licensed its patents on Januvia to Sun Pharma in India, a mandatory procedural requirement, which was missing when Merck and Sun Pharma filed a patent infringement suit against Glenmark on April 1. The two companies have formalized the licensing agreement, signed on May 16 and registered in the Patent Office on May 21.

However, this patent case will not impact the existing marketing tie-up between the two companies. Back in 2011, Merck and Sun Pharma entered into a partnership for marketing blockbuster diabetes drug Sitagliptin and one of its combinations in the country. Under the India-specific agreement, Sun Pharma will market the anti-diabetes drugs under different brand names, while Merck, which holds the patent, will continue to market Sitagliptin as Januvia.

Sun Pharma Inds. Share Price

1719.60 -0.15 (-0.01%)
01-Jan-2026 14:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.60
Dr. Reddys Lab 1250.85
Cipla 1499.55
Zydus Lifesciences 912.55
Lupin 2101.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×